Avalo Therapeutics (AVTX) Return on Sales (2016 - 2025)

Avalo Therapeutics (AVTX) has 10 years of Return on Sales data on file, last reported at 2.33% in Q4 2025.

• For the quarter ending Q4 2025, Return on Sales fell 48.0% year-over-year to 2.33%; the trailing twelve-month figure through Dec 2025 stood at 1.57% (down 77.0% YoY), and the FY2025 full-year result was 13.26%, down 1247.0% from the prior year.
• Return on Sales for Q4 2025 stood at 2.33%, down from 2.26% in the prior quarter.
• Across five years, Return on Sales topped out at 0.93% in Q3 2024 and bottomed at 2.33% in Q4 2025.
• The 5-year median for Return on Sales is 0.13% (2023), against an average of 0.45%.
• The widest annual swing landed in 2024, when Return on Sales jumped 115 bps; it then sank 319 bps in 2025.
• A 5-year view of Return on Sales shows it stood at 0.0% in 2021, then soared by 99 bps to 0.0% in 2022, then plunged by 382254 bps to 0.14% in 2023, then sank by 1187 bps to 1.84% in 2024, then slipped by 26 bps to 2.33% in 2025.
• The last three Return on Sales figures came in at 2.33% (Q4 2025), 2.26% (Q3 2025), and 1.84% (Q4 2024), per Business Quant data.

Peer Comparison